Payment overview · 2025
General Payments
$1,096.54
49 reported records · 15 companies
Healthcare provider profile · identity verified
Laurel Sockrider
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SURPRISE, AZ · NPI 1881132314
Verified facts
What the public records show
CMS Open Payments records show Laurel Sockrider received $1,096.54 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $243.45 | 22.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $179.35 | 16.4% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $136.92 | 12.5% | 7 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $99.42 | 9.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.41 | 7.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.75 | 5.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.34 | 5.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.56 | 4.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.76 | 4.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.25 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.97 | 2.6% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $26.77 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.55 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.64 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.40 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,096.54 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $213.33 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $207.70 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $99.42 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.09 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.14 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.14 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.34 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.06 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 190 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 45 |
| Trazodone Hcl | Trazodone Hcl | 155 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 47 |
| Lisinopril | Lisinopril | 136 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 40 |
| Donepezil Hcl | Donepezil Hcl | 118 | 23 |
| Losartan Potassium | Losartan Potassium | 116 | 52 |
| Gabapentin | Gabapentin | 109 | 39 |
| Omeprazole | Omeprazole | 107 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 23 |
| Furosemide | Furosemide | 97 | 20 |
| Mirtazapine | Mirtazapine | 91 | 22 |
| Sertraline Hcl | Sertraline Hcl | 88 | 27 |
| Tramadol Hcl | Tramadol Hcl | 79 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 29 |
| Alprazolam | Alprazolam | 76 | 38 |
| Mounjaro | Tirzepatide | 75 | 13 |
| Eliquis | Apixaban | 74 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 28 |
| Memantine Hcl | Memantine Hcl | 72 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 24 |
| Methylprednisolone | Methylprednisolone | 67 | 61 |
| Potassium Chloride | Potassium Chloride | 67 | 13 |
| Simvastatin | Simvastatin | 67 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Metformin Hcl | Metformin Hcl | 64 | 27 |
| Montelukast Sodium | Montelukast Sodium | 64 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 16 |
| Azithromycin | Azithromycin | 55 | 45 |
| Meloxicam | Meloxicam | 55 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 20 |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 39 |
| Risperidone | Risperidone | 47 | suppressed |
| Carvedilol | Carvedilol | 43 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 16 |
| Lorazepam | Lorazepam | 40 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 15 |
| Atenolol | Atenolol | 38 | 11 |
| Prednisone | Prednisone | 38 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 15 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 13 |
| Amoxicillin | Amoxicillin | 34 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 14 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Ozempic | Semaglutide | 33 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 23 |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Alendronate Sodium | Alendronate Sodium | 30 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 20 |
| Fluconazole | Fluconazole | 27 | 22 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 15 |
| Famotidine | Famotidine | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 15 |
| Estradiol | Estradiol | 23 | 15 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Valacyclovir | Valacyclovir Hcl | 16 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | 13 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,096.54 · 49 records | Novo Nordisk Inc | AIRSUPRA, AVEIR, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, LINZESS, Leqembi, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, VRAYLAR, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error